First-in-human imaging with 89Zr-Df-IAB2M Anti-PSMA minibody in patients with metastatic prostate cancer: Pharmacokinetics, biodistribution, dosimetry, and lesion uptake Academic Article uri icon

Overview

MeSH Major

  • Antigens, Surface
  • Carrier Proteins
  • Glutamate Carboxypeptidase II
  • Immunoglobulin Fragments
  • Immunoglobulins
  • Positron Emission Tomography Computed Tomography
  • Prostatic Neoplasms

abstract

  • (89)Zr-IAB2M is safe and demonstrates favorable biodistribution and kinetics for targeting metastatic prostate cancer. Imaging with 10 mg of minibody mass provides optimal biodistribution, and imaging at 48 h after injection provides good lesion visualization. Assessment of lesion targeting is being studied in detail in an expansion cohort.

publication date

  • December 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5450345

Digital Object Identifier (DOI)

  • 10.2967/jnumed.116.176206

PubMed ID

  • 27516450

Additional Document Info

start page

  • 1858

end page

  • 1864

volume

  • 57

number

  • 12